Effect of zinc in treatment of gestational diabetes

Effect of zinc supplementation on biomarkers of inflammation, stress oxidative and pregnancy outcomes in women with gestational diabetes

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201505095623N42

Enrollment

Registered

2015-05-22

Start date

2014-10-27

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gestational diabetes. Diabetes mellitus in pregnancy, unspecified

Interventions

Intervention 1: Intervention group: Zinc capsule, 30 mg, daily for 6 weeks orally. Intervention 2: Control group: Placebo capsule, daily for 6 weeks orally.

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Pregnant women aged 18-40 years diagnosed with GDM at 24-28 weeks' gestation

Exclusion criteria

Exclusion criteria: The use of substitute treatments including hormone or vitamin supplements patients with preeclampsia complete bed rest (CBR) intra uterine fetal death (IUFD) placenta abruption preterm delivery

Design outcomes

Primary

Measure	Time frame
Hs-CRP. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;Newborns PPAR-gamma. Timepoint: Cord blood of newborns of women with GDM at delivery time. Method of measurement: PCR-RT.	—

Secondary

Measure	Time frame
Total antioxidant capacity. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Nitric oxide. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Newborns' weight. Timepoint: The first 24 h after birth. Method of measurement: Scale.;Newborn length. Timepoint: The first 24 h after birth. Method of measurement: Girth measuring tape.;Newborn head circumference. Timepoint: The first 24 h after birth. Method of measurement: Girth measuring tape.;Polyhydramnios. Timepoint: Post-intervention. Method of measurement: Sonography.;Newborns GLUT. Timepoint: Cord blood of newborns of women with GDM at delivery time. Method of measurement: PCR-RT.	—

Measure

Time frame

Total antioxidant capacity. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Nitric oxide. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Newborns' weight. Timepoint: The first 24 h after birth. Method of measurement: Scale.;Newborn length. Timepoint: The first 24 h after birth. Method of measurement: Girth measuring tape.;Newborn head circumference. Timepoint: The first 24 h after birth. Method of measurement: Girth measuring tape.;Polyhydramnios. Timepoint: Post-intervention. Method of measurement: Sonography.;Newborns GLUT. Timepoint: Cord blood of newborns of women with GDM at delivery time. Method of measurement: PCR-RT.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZatollah Asemi

Kashan University of Medical Sciences

asemi_r@yahoo.com+98 31 5554 0021

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026